1.48
+4.96%
Close of 9 Nov 2026, in CAD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Cardiol Therapeutics
Its shares trade on Toronto Stock Exchange under the ticker CRDL.TO. It has been listed since 20 December 2018. In the fiscal year to 31 December 2021, it reported revenue of C$78,760 and a net loss of C$24.7m. At that date it held total assets of C$87.9m and shareholders' equity of C$76.2m.
Cardiol Therapeutics, Inc. is a biotechnology company, which engages in the research and commercial development of pharmaceutical cannabidiol products and targeted therapies for inflammatory diseases. The company is headquartered in Oakville, Ontario. The company went IPO on 2018-12-20. The firm is focused on the research and commercial development of pharmaceutical cannabidiol products and targeted therapies for heart failure and cancer. The company has research programs focused on development of nanotherapeutics to treat heart failure underway. The firm invests in development of formulations for three medical markets: commercializing a line of purity pharmaceutically-manufactured cannabidiol products in the market for medical cannabinoids; development of nanotechnologies designed to deliver cannabinoids and other anti-inflammatory drugs for the treatment of heart failure, a cause of death and hospitalization, and pursuing an immunotherapeutics program commencing with a cancer immunotherapeutic in combination with cannabinoids for treating Glioblastoma Multiforme.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 20 Dec 2018
- Employees
- 11
- Website
- cardiolrx.com ↗
Leadership
Pay as last reported
- Dr. Guillermo Torre-AmioneIndependent Chairman of the BoardC$382,861
- Mr. David ElsleyPresident, Chief Executive Officer, Director, since 2017C$1.7m
- Mr. Christopher WaddickChief Financial Officer, Corporate Secretary, Director, since 2018C$1.0m
- Mr. Bernard LimChief Operating OfficerC$1.3m
- Dr. Andrew HamerChief Medical Officer, Head of Research and DevelopmentC$1.5m
- Dr. Timothy GarnettDirector
- Ms. Jennifer ChaoIndependent DirectorC$403,949
- Ms. Teri LoxamIndependent DirectorC$350,865
- Mr. Peter PekosIndependent DirectorC$331,743
- Mr. Colin StottIndependent DirectorC$333,542
- Mr. Michael WillnerIndependent DirectorC$339,858
- Mr. Trevor BurnsInvestor Relations
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 34
- Environment
- 33
- Social
- 60
- Governance
- 10
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Cardiol Therapeutics Inc has a strong research and development capability, allowing them to innovate and develop novel therapies for cardiovascular diseases.
- The company has a dedicated and highly skilled team of scientists and medical professionals who are experts in the field of cardiology.
- Cardiol Therapeutics Inc has a robust intellectual property portfolio, which provides them with a competitive advantage and protects their innovations.
Weaknesses
- The company is relatively small in size and may have limited financial resources compared to larger pharmaceutical companies, which can hinder their ability to fund extensive clinical trials and commercialize their products.
- Cardiol Therapeutics Inc relies heavily on external funding and partnerships for research and development activities, which may introduce uncertainties and dependencies.
Opportunities
- There is a growing demand for innovative cardiovascular therapies due to the increasing prevalence of cardiovascular diseases globally, presenting a significant market opportunity for Cardiol Therapeutics Inc.
- Advancements in technology and personalized medicine open avenues for the development of targeted therapies, for which Cardiol Therapeutics Inc is well-equipped.
- The company can leverage collaborative partnerships with academic institutions, government organizations, and other pharmaceutical companies to gain access to additional resources and expertise.
Threats
- The pharmaceutical industry is highly regulated, and obtaining necessary approvals and complying with regulatory requirements can be time-consuming and costly, posing a threat to Cardiol Therapeutics Inc's development timeline and financial stability.
- Competition in the cardiovascular therapeutics market is intense with well-established players dominating the industry, making it challenging for Cardiol Therapeutics Inc to gain market share.
- External factors such as economic uncertainties, changes in healthcare policies, and global pandemics can impact Cardiol Therapeutics Inc's operations and funding sources.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.